Edition:
India

CymaBay Therapeutics Inc (CBAY.OQ)

CBAY.OQ on NASDAQ Stock Exchange Capital Market

14.98USD
16 Feb 2018
Change (% chg)

$0.11 (+0.74%)
Prev Close
$14.87
Open
$14.85
Day's High
$15.25
Day's Low
$14.56
Volume
315,368
Avg. Vol
217,589
52-wk High
$15.25
52-wk Low
$2.59

Select another date:

Tue, Jan 30 2018

BRIEF-CymaBay Announces Proposed Public Offering Of Common Stock

* CYMABAY THERAPEUTICS INC - ‍ANTICIPATES USING NET PROCEEDS FROM OFFERING TO FUND ONGOING DEVELOPMENT OF SELADELPAR​ Source text for Eikon: Further company coverage:

BRIEF-Cymabay Therapeutics Receives $5 Mln Milestone Payment For Arhalofenate From Kowa Pharmaceuticals America

* CYMABAY THERAPEUTICS RECEIVES $5 MILLION MILESTONE PAYMENT FOR ARHALOFENATE FROM KOWA PHARMACEUTICALS AMERICA Source text for Eikon: Further company coverage:

BRIEF-Cymabay Therapeutics Says First Primary Biliary Cholangitis Patients Have Been Successfully Enrolled In Seladelpar Long-Term Extension Study

* CYMABAY THERAPEUTICS INC - FIRST PRIMARY BILIARY CHOLANGITIS PATIENTS HAVE BEEN SUCCESSFULLY ENROLLED IN SELADELPAR LONG-TERM EXTENSION STUDY Source text for Eikon: Further company coverage:

BRIEF-CymaBay Therapeutics Files For Mixed Shelf Of Up To $200 Mln

* CYMABAY THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (http://bit.ly/2pRWkXa) Further company coverage:

BRIEF-CymaBay reports Q3 loss per share $0.21

* CymaBay reports third quarter 2017 financial results and corporate updates

BRIEF-Cymabay to deliver interim results from ongoing phase 2 study of Seladelpar at AASLD 2017

* Cymabay announces oral late-breaking presentation of interim results from an ongoing Phase 2 study of patients with primary biliary cholangitis at the AASLD 2017 Liver Meeting

BRIEF-CymaBay Therapeutics granted EMA orphan drug designation for seladelpar

* CymaBay Therapeutics granted EMA orphan drug designation for seladelpar for the treatment of primary biliary cholangitis Source text for Eikon: Further company coverage:

Select another date: